La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Avenue Therapeutics Croissance future

Future contrôle des critères 0/6

Avenue Therapeutics devrait augmenter ses bénéfices et ses revenus de 21.2% et de 95.3% par an respectivement, tandis que le BPA devrait croître de croître de 59.9% par an.

Informations clés

21.2%

Taux de croissance des bénéfices

59.9%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	95.3%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	12 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ATXI - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-17	N/A	N/A	1
12/31/2025	N/A	-14	N/A	N/A	1
12/31/2024	N/A	-13	N/A	N/A	1
6/30/2024	N/A	-15	-10	-9	N/A
3/31/2024	N/A	-11	-14	-11	N/A
12/31/2023	N/A	-10	-12	-9	N/A
9/30/2023	N/A	-10	-14	-11	N/A
6/30/2023	N/A	-12	-13	-11	N/A
3/31/2023	N/A	-8	-7	-7	N/A
12/31/2022	N/A	-4	-8	-8	N/A
9/30/2022	N/A	-5	-5	-5	N/A
6/30/2022	N/A	-5	-5	-5	N/A
3/31/2022	N/A	-6	-4	-4	N/A
12/31/2021	N/A	-4	-4	-4	N/A
9/30/2021	N/A	-4	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-5	-5	N/A
9/30/2020	N/A	-10	-8	-8	N/A
6/30/2020	N/A	-11	-9	-9	N/A
3/31/2020	N/A	-16	-22	-22	N/A
12/31/2019	N/A	-26	-26	-26	N/A
9/30/2019	N/A	-24	-23	-23	N/A
6/30/2019	N/A	-25	-25	-25	N/A
3/31/2019	N/A	-22	-17	-17	N/A
12/31/2018	N/A	-22	-18	-18	N/A
9/30/2018	N/A	-24	-21	-21	N/A
6/30/2018	N/A	-24	-19	-19	N/A
3/31/2018	N/A	-22	N/A	-14	N/A
12/31/2017	N/A	-12	N/A	-7	N/A
9/30/2017	N/A	-7	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-1	N/A
3/31/2017	N/A	-3	N/A	-1	N/A
12/31/2016	N/A	-3	N/A	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ATXI devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ATXI devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ATXI devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: ATXI ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: ATXI ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ATXI devrait être élevé dans 3 ans

Avenue Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 1,500% to US$900

Forecast breakeven pushed back to 2024

Price target lowered to US$9.00

Recent updates

New major risk - Financial position

Price target increased by 1,500% to US$900

Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Now 570% overvalued after recent price rise

New major risk - Revenue and earnings growth

Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy

Avenue Therapeutics, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

New major risk - Revenue and earnings growth

the Staff of Nasdaq Determines to Delist Avenue Therapeutics’ Securities from Nasdaq Based Upon its Continued Non-Compliance with the Rule

New major risk - Financial position

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $5 million.

New major risk - Share price stability

Avenue Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Executive Director recently bought US$251k worth of stock

Avenue Therapeutics, Inc. Announces High Potency and Full Efficacy in A Model of Generalized Seizures for Its Novelgaba-A Receptor Potentiator, Baer-101, Supporting Phase 2 Clinical Study

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics, Inc. Reaches Agreement with U.S. Food and Drug Administration on Key Elements of Phase 3 Safety Study for Intravenous Tramadol

Avenue Therapeutics Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding

Avenue Therapeutics, Inc., Annual General Meeting, Dec 28, 2022

Avenue Therapeutics, Inc. (NasdaqCM:ATXI) acquired Baergic Bio, Inc.

Avenue Therapeutics, Inc. Announces Board Resignations

Avenue Therapeutics, Inc. has completed a Composite Units Offering in the amount of $27.6 million.

Avenue Therapeutics shares slide on pricing $12M securities offering

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Avenue Therapeutics, Inc. Submits Type A Meeting Request and Related Briefing Documents to the FDA

Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer

Less than half of directors are independent

Avenue Therapeutics, Inc. Announces Management Changes

Avenue Therapeutics Receives Non-Compliance Letter from Nasdaq

Avenue Therapeutics, Inc. Announces CEO Changes

Less than half of directors are independent

Avenue Therapeutics, Inc. Receives an Acknowledgement Letter from the Office of New Drugs of the Food and Drug Administration Regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request

Avenue Therapeutics, Inc.(NasdaqCM:ATXI) dropped from Russell 3000E Index

Forecast breakeven pushed back to 2024

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Resubmits New Drug Application to the U.S. Food and Drug Administration for IV Tramadol

New 90-day high: US$6.93

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics, Inc. Provides Regulatory Update for IV Tramadol

Avenue Therapeutics issues regulatory update for IV tramadol

Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020

New 90-day low: US$2.95

Avenue Therapeutics, Inc. Receives Complete Response Letter from the FDA for IV Tramadol

New 90-day low: US$4.53

Price target lowered to US$9.00

New 90-day high - US$12.06

New 90-day high - US$11.68

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance